Literature DB >> 17426069

Low-dose remifentanil to suppress haemodynamic responses to noxious stimuli in cardiac surgery: a dose-finding study.

B Steinlechner1, M Dworschak, B Birkenberg, T Lang, A Schiferer, A Moritz, B Mora, A Rajek.   

Abstract

BACKGROUND: High-dose remifentanil (1-5 microg kg-1 min-1), commonly used for cardiac surgery, has been associated with muscle rigidity, hypotension, bradycardia, and reduced cardiac output. The aim of this study was to determine an optimal lower remifentanil dose, which should be accompanied by fewer adverse events, that still effectively suppresses haemodynamic responses to typical stressful stimuli (i.e. intubation, skin incision, and sternotomy).
METHODS: Total i.v. anaesthesia consisted of a target-controlled propofol (2 microg ml-1) and a remifentanil infusion. Forty patients were allocated to receive either a constant infusion of remifentanil at 0.1 microg kg-1 min-1 or up-titrations to 0.2, 0.3, or 0.4 microg kg-1 min-1, respectively, 5 min before each stimulus. Subsequently, changes in heart rate and mean arterial blood pressure were recorded for 8 min. Increases exceeding 20% of baseline were considered to be of clinical relevance. Patients who exhibited these alterations were termed responders.
RESULTS: The number of responders was less with the two higher remifentanil dosages (P<0.05) while propofol target doses could either be kept at the same level or even be reduced without affecting the plane of anaesthesia. Although single phenylephrine bolus had to be applied more frequently in these two groups (P<0.05), no severe haemodynamic depression was observed.
CONCLUSIONS: Remifentanil at 0.3 and 0.4 microg kg-1 min-1 in combination with a target-controlled propofol infusion in the pre-bypass period is well tolerated. It appears to mitigate potentially hazardous haemodynamic responses from stressful stimuli equally well as higher doses when compared with data from the literature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426069     DOI: 10.1093/bja/aem069

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  7 in total

1.  Total Intravenous Anesthesia-Target Controlled Infusion for colorectal surgery. Remifentanil TCI vs sufentanil TCI.

Authors:  Horaţiu Nicolae Vasian; Simona Mărgărit; Daniela Ionescu; Anamaria Keresztes; Bogdan Arpăşteuan; Nicoleta Condruz; Camelia Coadă; Iurie Acalovschi
Journal:  Rom J Anaesth Intensive Care       Date:  2014-10

Review 2.  Anaesthetic considerations for pectus repair surgery.

Authors:  Chinmay Patvardhan; Guillermo Martinez
Journal:  J Vis Surg       Date:  2016-04-11

Review 3.  Could remifentanil reduce duration of mechanical ventilation in comparison with other opioids for mechanically ventilated patients? A systematic review and meta-analysis.

Authors:  Yibing Zhu; Yinhua Wang; Bin Du; Xiuming Xi
Journal:  Crit Care       Date:  2017-08-03       Impact factor: 9.097

4.  Remifentanil preconditioning protects against hypoxia-induced senescence and necroptosis in human cardiac myocytes in vitro.

Authors:  Anna Lewinska; Jagoda Adamczyk-Grochala; Dominika Bloniarz; Beata Horeczy; Slawomir Zurek; Arkadiusz Kurowicki; Bogumila Woloszczuk-Gebicka; Kazimierz Widenka; Maciej Wnuk
Journal:  Aging (Albany NY)       Date:  2020-06-25       Impact factor: 5.682

Review 5.  Preintervention imaging and intraoperative management care of the hypertrophic obstructive cardiomyopathy patient.

Authors:  Jacobo Moreno Garijo; Cristina Ibáñez; Juan M Perdomo; Martin D Abel; Massimiliano Meineri
Journal:  Asian Cardiovasc Thorac Ann       Date:  2021-09-24

6.  Comparison of the Effect of Anesthesia With Midazolam-Fentanyl Versus Propofol-Remifentanil on Bispectral Index in Patients Undergoing Coronary Artery Bypass Graft.

Authors:  Naser Hemmati; Abdol Hamid Zokaei
Journal:  Glob J Health Sci       Date:  2015-03-18

7.  A case series of continuous paravertebral block in minimally invasive cardiac surgery.

Authors:  Shintaro Tahara; Akito Inoue; Hajime Sakamoto; Yasuaki Tatara; Kayoko Masuda; Yoichiro Hattori; Yusaku Nozumi; Mitsumasa Miyagi; Surakshya Sigdel
Journal:  JA Clin Rep       Date:  2017-08-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.